A systematic review of primary outcomes and outcome measure reporting in randomized trials evaluating treatments for pre-eclampsia by Duffy, James MN et al.
 1 
 
Primary outcome and outcome measure reporting in randomized 1 
trials evaluating treatments for preeclampsia: a systematic review. 2 
 3 
Dr James M. N. Duffy1, Dr Martin Hirsch2,3, Dr Chris Gale4, Dr Louise Pealing1, Dr 4 
Anusuya Kawsar3, Mrs Marian Showell5, Prof Paula R. Williamson6, Prof Khalid S. 5 
Khan2, Prof Sue Ziebland1, NIHR Prof Richard J. McManus1 6 
 7 
On behalf of the International Collaboration to Harmonize Outcomes in Preeclampsia 8 
(iHOPE) *steering committee listed at the end of the manuscript. 9 
 10 
1 Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, 11 
United Kingdom. 12 
2 Women's Health Research Unit, Queen Mary, University of London, London, 13 
United Kingdom.   14 
3 Royal Free London NHS Trust, London, United Kingdom. 15 
4 Neonatal Medicine, Faculty of Medicine, Imperial College London, London, United 16 
Kingdom. 17 
5 Cochrane Gynaecology and Fertility Group, University of Auckland, Auckland, New 18 
Zealand. 19 
6 MRC North West Hub for Trials Methodology Research, Institute of Translational 20 
Medicine, University of Liverpool, Liverpool, United Kingdom. 21 
 22 
Correspondence to: 23 
Dr James M N Duffy MBChB MRes BSc (Hons) PG HCL 24 
Balliol College, University of Oxford, Oxford OX2 6GG, United Kingdom. 25 
+44 (0)1865 289298 26 
james.duffy@balliol.ox.ac.uk 27 
 28 
Keywords:  29 
(1) Core outcome sets; (2) Newborn; (3) Outcome reporting bias; (4) Preeclampsia; 30 
(5) Randomized controlled trials; and (6) Systematic review. 31 
 32 
Synopsis:  33 
Randomized trials evaluating treatments for preeclampsia often omit critical 34 
information related to their primary outcome, including definition and measurement.  35 
A core outcome set is required. 36 
 37 
Word count of the main text: 38 
1,762 words 39 
 40 
 41 
 42 
 43 
 2 
 
Abstract 44 
Background: To develop a core outcome set an evaluation of primary outcome and 45 
outcome measure reporting is required. 46 
Objectives: To assess primary outcome and outcome measure reporting across 47 
randomized trials evaluating treatments for preeclampsia. 48 
Search strategy: We searched Cochrane Central Register of Controlled Trials, 49 
Cumulative Index to Nursing and Allied Health Literature, EMBASE, MEDLINE, and 50 
PsycINFO from inception to January 2016. 51 
Selection criteria: Randomized trials evaluating treatments for preeclampsia. 52 
Data collection and analysis: We systematically extracted and categorized primary 53 
outcome and outcome measure reporting. 54 
Main results: Seventy-nine randomized trials, including data from 31,615 maternal 55 
participants were included. Thirty-eight trials (48%) reported 35 different primary 56 
outcomes, of which 28 were maternal outcomes and seven were offspring outcomes.  57 
Three randomized trials reported composite outcomes including between seven and 58 
nine outcome components. The method of definition or measurement was 59 
infrequently or poorly reported within trial reports. When outcomes were consistently 60 
reported across trials, different methods of definition or measurement were 61 
frequently described. 62 
Conclusions: Randomized trials evaluating interventions for preeclampsia regularly 63 
omit critical information related to their primary outcome, including definition and 64 
measurement. Developing a core outcome set for preeclampsia trials should help 65 
inform primary outcome and outcome measure selection. 66 
 67 
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Introduction 68 
Preeclampsia, a pregnancy specific multisystem syndrome, is a common cause of 69 
maternal and offspring mortality and morbidity.(1) Interventions capable of reducing 70 
this substantial health burden are urgently required. Randomized trials are the best 71 
way of establishing the efficacy and safety of new treatments; but are only as 72 
credible as their primary outcomes.(2) There is currently no consensus regarding the 73 
selection of primary outcomes and methods of definition or measurement for 74 
preeclampsia trials.(3) The primary outcome should be the outcome of greatest 75 
therapeutic importance to the study’s prospective hypothesis.(4) In the absence of a 76 
standardized approach, researchers may make arbitrary decisions when selecting 77 
between several important outcomes.(5) Within the context of preeclampsia, the 78 
requirement to evaluate efficacy and safety within maternal participants and their 79 
offspring provides additional complexity. Outcome reporting bias may occur should 80 
this selection occur retrospectively based upon statistical significance of the results. 81 
(6, 7) 82 
 83 
Researchers may need to make pragmatic decisions and select a less informative 84 
primary outcome when designing trials, influenced by factors such as sample size 85 
requirement, costs, and time.(8) The selection of a composite outcome could 86 
increase statistical efficiency because of higher event rates and avoids arbitrary 87 
choices between several important outcomes, reflecting the multisystem 88 
preeclampsia syndrome.(9) Researchers may be unable to select otherwise 89 
appropriate outcomes because of the lack of objective definitions or validated 90 
instruments. 91 
 92 
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The first step in developing a core outcome set for preeclampsia requires an 93 
evaluation of primary outcome and outcome measure reporting.(3) Therefore, we 94 
assessed the consistency of primary outcome reporting, including the adequacy of 95 
information pertaining to definition and measurement, across randomized trials 96 
evaluating treatments for preeclampsia. 97 
 98 
Materials and methods 99 
A protocol with explicitly defined objectives, criteria for study selection, approaches 100 
to assessing study quality, and statistical methods was developed. We have reported 101 
the systematic review in accordance with the Preferred Reporting Items for 102 
Systematic Reviews and Meta-Analyses (PRISMA) statement.(10) 103 
 104 
A systematic literature review was undertaken searching the Cochrane Central 105 
Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied 106 
Health Literature (CINHAL), MEDLINE, EMBASE, and PsycINFO, from the inception 107 
to January 2016 (Appendix S1). Two authors independently screened each 108 
potentially relevant record based on title and abstract then reviewed the full text of 109 
each selected study to assess eligibility. Discrepancies between the authors were 110 
resolved through discussion. 111 
 112 
We included randomized controlled trials evaluating the efficacy of any treatment for 113 
preeclampsia. We did not exclude trials in mixed populations of antenatal or 114 
postnatal participants. We did not exclude trials in mixed populations of participants 115 
with preeclampsia and chronic hypertension and / or gestational hypertension. We 116 
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applied no restrictions for languages or publication date and translated two trial 117 
reports. 118 
 119 
Using a pilot-tested and standardized data extraction form, two authors 120 
independently extracted study characteristics including participants, interventions, 121 
and outcomes. Discrepancies between authors were resolved through discussion. 122 
We did not contact authors to clarify primary outcomes or outcome measures which 123 
were unclearly reported. 124 
 125 
We developed a comprehensive inventory of primary outcomes.  If a primary 126 
outcome was not explicitly stated, we extracted the outcome included in the study’s 127 
power calculation. We initially organized outcomes into two broad categories: 128 
maternal and offspring outcomes. We subsequently organized these outcomes into 129 
individual domains, in consultation with healthcare professionals, researchers, and 130 
patients.  We used descriptive statistics to characterize our included trials, mapping 131 
primary outcomes and their methods of definition or measurement across included 132 
trials. 133 
 134 
Results 135 
We discovered 10,720 records, after excluding 3,627 duplicate records, 7,093 titles 136 
and abstracts were screened, and 162 potentially relevant studies were examined 137 
(Figure 1). Seventy-nine randomized trials, reporting data from 31,615 maternal 138 
participants, met our inclusion criteria. Nearly half of included trials (38 trials; 48%) 139 
reported a primary outcome.(11-48) 140 
 141 
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Thirty-five different primary outcomes were reported, of which 28 were maternal 142 
outcomes and seven offspring outcomes. These outcomes were organized in 143 
consultation with health care professionals, researchers, and patients into 16 144 
domains, including five maternal domains and five offspring domains (Table 1). 145 
 146 
Primary maternal outcomes more frequently reported included blood pressure (10 147 
trials; 13%), eclampsia (7 trials; 9%), maternal mortality (3 trials; 4%), and pulmonary 148 
edema (3 trials; 4%). Primary offspring outcomes were infrequently reported, for 149 
example, Offspring mortality was reported by two trials (3%), neonatal respiratory 150 
distress syndrome was reported by a single trial (1%), and a single trial (1%) 151 
reported neurological development (Table 1). 152 
 153 
Three trials (4%) reported composite outcomes (Table 1). The number of 154 
components ranged from seven to nine. Two components, maternal mortality and 155 
pulmonary edema, was common to all composite outcomes. Only one trial (1%) 156 
included an offspring outcome, neonatal repository distress syndrome, within the 157 
composite outcomes. The components of the composite outcome did not change in 158 
the three trial reports between the abstract, methods, and results. Six trials (8%) 159 
reported more than one primary outcome. Three trials (3%) reported more than one 160 
primary maternal outcome (range 2-3 outcomes). A single trial (1%) reported two 161 
primary offspring outcomes. Two trials (3%) reported primary maternal and offspring 162 
outcomes (range 2-3 outcomes). 163 
 164 
Thirty-four different methods of definition or measurement were reported (Table 2). 165 
Even when outcomes were consistently reported across included trials, different 166 
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methods of definition or measurement were described. For example, blood pressure 167 
was reported in three different ways: (1) systolic blood pressure; (2) diastolic blood 168 
pressure; (3) mean arterial blood pressure. 169 
  170 
Discussion 171 
Randomized trials evaluating interventions for preeclampsia regularly omit 172 
information pertaining to primary outcomes and outcome measures. Nearly half of 173 
included trials explicitly reported a primary outcome. When primary outcomes were 174 
consistently reported across trials, different methods of definition or measurement 175 
were frequently described.   Such variation contributes to an inability to compare, 176 
contrast, and combine individual studies and limits the usefulness of research to 177 
inform clinical practice. 178 
 179 
The strengths of this systematic review include its originality, comprehensive search 180 
strategy, methodological design, and statistical analysis.  To our knowledge, this is 181 
the first systematic review to map primary outcomes and their means of definition 182 
and measurement in preeclampsia trials. To prevent bias in the review process, 183 
study selection, and data extraction and assessment were conducted independently 184 
by two authors. An international steering group, including women with lived 185 
experience of preeclampsia, was formed to oversee the study, their input was central 186 
to the development of a comprehensive inventory of primary outcomes. 187 
 188 
Our empirical evaluation has limitations. We considered those outcomes which were 189 
included within a sample size calculation as a primary outcome. The lack of explicit 190 
primary outcome in many trials meant that we occasionally mapped outcomes which 191 
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were not recorded as primary outcomes within the trial report. We did not contact 192 
authors to clarify primary outcomes or outcome measures which appeared unclear. 193 
Primary outcomes, especially in earlier phase efficacy trials, may be chosen to 194 
reflect the aim of the intervention. We would not necessarily expect the primary 195 
outcome for trials of antihypertensives to be the same as anticonvulsants. Examining 196 
primary outcome reporting and its relationship with other factors including year of 197 
publication, commercial funding, and journal impact factor could provide additional 198 
understanding.(49, 50) However, no validated outcome reporting quality assessment 199 
tools currently exist, limiting our ability to undertake this analysis.  200 
 201 
The Global Pregnancy CoLaboratory, an international collaboration involving key 202 
stakeholders including healthcare professionals, researchers, and women with lived 203 
experience of preeclampsia, have published a strategy to standardize preeclampsia 204 
research study design including data set standards for research studies.(51) Their 205 
work reflects the enthusiasm of the pre-eclampsia research community to work 206 
together to improve research design and clinical care. The next challenge is to 207 
address poor outcome reporting driving outcome reporting bias by developing and 208 
implementing core outcome sets.  209 
 210 
The Core Outcomes in Women’s and Newborn Health (CROWN) initiative has been 211 
formed to tackle the challenge of addressing the unwarranted variation in outcome 212 
collection and reporting.(52) Participating journals aim to reduce research waste by 213 
facilitating consistent reporting of core outcomes.(53) Core outcome sets are 214 
minimum collections of outcomes that are predefined, measured in a standardized 215 
manner, and reported consistently in the final publication.(54) The outcomes do not 216 
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need to be extensive and researchers remain free to measure and report other 217 
outcomes. Ideally the primary outcome and outcome measure should be selected 218 
from the core outcome set. The Core Outcome Measures for Efficacy Trials 219 
(COMET) initiative advocates the development of core outcome sets by groups 220 
including healthcare professionals, researchers, and patients. Their development 221 
typical includes three broad stages: (1) identifying potential core outcomes; (2) 222 
determining core outcomes using robust consensus methods engaging key 223 
stakeholders, and (3) determining how core outcomes should be measured.(8, 54) 224 
Several consortiums have been established developing core outcome sets across 225 
our specialty.(55-57)  226 
 227 
An international steering group, including healthcare professionals, researchers, and 228 
patients, has been formed to develop a core outcome set for preeclampsia. The 229 
inventory of primary outcomes identified by this systematic review has contributed to 230 
the long list of outcomes entered into a modified Delphi method. Consensus ‘core’ 231 
outcomes for pre-eclampsia have been identified by 283 healthcare professionals, 232 
41 researchers, and 112 patients from 55 countries.(58)  233 
 234 
In conclusion, randomized trials evaluating interventions for preeclampsia regularly 235 
omit information related to the primary outcome and its definition or measurement. 236 
Implementing a core outcome set in future preeclampsia trials should help inform 237 
primary outcome and outcome measure selection and facilitate consistent reporting. 238 
 239 
 240 
 241 
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